Patients' impatience is an independent determinant of poor diabetes control

Diabetes and Metabolism

Volumn 37, Issue 6, 2011, Pages 497-504

  Reach, G ^a,c   Michault, A ^b   Bihan, H ^a   Paulino, C ^b   Cohen, R ^a   Le Clesiau H ^b  

^a UNIVERSITÉ PARIS 13   (France)

^b Centre d'Examens de Santé de la Caisse Primaire d'Assurance Maladie de Seine Saint Denis   (France)

^c UNIVERSITÉ PARIS 13   (France)

Author keywords

Adherence; Clinical myopia; Foresight; Impatience; Locus of control; Monetary choice; Social deprivation; Temporal horizon; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES CONTROL; DISEASE ASSOCIATION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; SOCIAL ISOLATION; TREATMENT OUTCOME;

CHOICE BEHAVIOR; CROSS-SECTIONAL STUDIES; DECISION TREES; DIABETES MELLITUS, TYPE 2; FEMALE; FRANCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; QUESTIONNAIRES; SELF CARE; SOCIOECONOMIC FACTORS;

EID: 83255186883     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2011.03.004     Document Type: Article

References (25)

1. Ainslie G. Précis of Breakdown of will. Behav Brain Sci 2005, 28:635-650.
2. Rachlin H., Raineri A., Cross D. Subjective probability and delay. J Exp Anal Behav 1991, 55:233-244.
3. Bickel W.K., Miller M.L., Yi R., Kowal B.P., Lindquist D.M., Pitcock J.A. Behavioral and neuroeconomics of drug addiction: competing neural systems and temporal discounting processes. Drug Alcohol Dependence 2007, 90S:S85-S91.
4. Christakou A., Brammer M., Rubia K. Maturation of limbic corticostriatal activation and connectivity associated with developmental changes in temporal discounting. Neuroimage 2011, 54:1344-1354.
5. val/val genotype. J Neurosci 2007, 27:14383-14391.
6. Reach G. Personal view: is there an impatience genotype leading to non-adherence to long term therapies?. Diabetologia 2010, 53:1562-1567.
7. Chapman G.B., Brewer N.T., Coups E.J., Browlee S., Leventhal H., Leventhal E.A. Value for the future and preventive health behavior. J Exp Psychol 2001, 7:235-250.
8. Trento M., Tomelini M., Basile M., Borgo E., Passera P., Miselli V., et al. The locus of control in patients with Type 1 and Type 2 diabetes managed by individual and group care. Diabet Med 2008, 25:86-90.
9. Bihan H., Laurent S., Sass C., Nguyen G., Huot C., Moulin J.J., et al. Association among individual deprivation, glycemic control, and diabetes complications: the EPICES score. Diabetes Care 2005, 28:2680-2685.
10. Girerd X., Hanon O., Anagnostopoulos K., Ciupek C., Mourad J.J., Consoli S. Evaluation de l'observance du traitement antihypertenseur par un questionnaire : mise au point et utilisation dans un service spécialisé. Presse Med 2001, 30:1044-1048.
11. Wallston B.S., Wallston K.A. Locus of control and health: a review of the literature 1978, Health education monographs, Spring, p. 107-17.
12. Sass C., Moulin J.J., Guéguen R., Abric L., Dauphinot V., Dupré C., et al. Le score Epices : un score individuel de précarité. Construction du score et mesure des relations avec des données de santé, dans une population de 197 389 personnes. BEH 2006, 14:93-95.
13. (access January 25, 2010). http://www.cetaf.asso.fr/publications/RE_precarite.pdf.
14. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 28:2005-2012.
15. Lawrence D.B., Ragucci K.R., Long L.B., Parris B.S., Helfer L.A. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and Hemoglobin A1c goal attainment for HMO patients enrolled in a Diabetes Disease Management Program. J Manag Care Pharm 2006, 12:466-471.
16. Wamala S., Merlo J., Bostrom G., Hogstedt C., Agren G. Socioeconomic disadvantage and primary non-adherence with medication in Sweden. Int J Qual Health Care 2007, 19:134-140.
17. Johnson M.V.V., Bickel W.K. Within-subject comparison of real and hypothetical money rewards in delay discounting. J Exp Anal Behav 2002, 77:129-146.
18. Perry J.L., Carroll M.E. The role of impulsive behavior in drug abuse. Psychopharmacology 2008, 200:1-26.
19. Takahashi T., Oono H., Inoue T., Boku S., Kako Y., Kitaichi Y., et al. Depressive patients are more impulsive and inconsistent in intertemporal choice behavior for monetary gain and loss than healthy subjects--an analysis based on Tsallis' statistics. Neuro Endocrinol Lett 2008, 29:351-358.
20. Weller R.E., Cook EW, Aswar K.B., Cox J.E. Obese women show greater delay discounting than healthy-weight women. Appetite 2008, 51:563-569.
21. Briesacher B.A., Andrade S.E., Fouayzi H., Chan K.A. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008, 28:437-443.
22. Bickel W.K., Yi R., Kowal B.P., Gatchalian K.M. Cigarette smokers discount past and future rewards symmetrically and more than controls: Is discounting a measure of impulsivity?. Drug Alcohol Depend 2008, 96:256-262.
23. WHO, Adherence to long term therapies, evidence for action, WHO Library Cataloguing-in-Publication Data, Genève, 2003.
24. Reach G. Patient non-adherence and healthcare-provider inertia are clinical myopia. Diabetes Metab 2008, 34:382-385.
25. Ortendahl M., Fries J.F. Discounting and risk characteristics in clinical-decision making. Med Sci Monit 2006, 12:RA41-RA45.